Today: 27 June 2026
Diageo share price ends week higher after Sheridan’s sale closes, eyes Feb 25 results
31 January 2026
2 mins read

Diageo share price ends week higher after Sheridan’s sale closes, eyes Feb 25 results

London, Jan 31, 2026, 08:22 GMT — Market closed

  • Diageo shares ended Friday 2.3% higher, closing at 1,675.5 pence
  • Company has finalized the sale of Sheridan’s liqueur to Casa Redondo
  • Investors are now turning their attention to Diageo’s interim results update, due on Feb. 25

Diageo (DGE.L) shares climbed 2.3% to close at 1,675.5 pence on Friday following the announcement that it completed the sale of Sheridan’s to Casa Redondo. Despite the gain, the stock remains far below its 52-week peak. Trading volume reached roughly 8.1 million shares, according to LSEG data.

Why it matters now: Diageo is trimming its portfolio bit by bit as investors look for firmer evidence the company can stabilize demand and safeguard margins. These minor sales usually don’t shift forecasts, yet they reinforce the narrative—focused portfolio management, cash generation, and discipline—just when the market is quick to slam any sign of weakening consumer spending.

The broader context is playing a role as well. The FTSE 100 ended Friday up 0.5%, while sterling slipped about 0.6% against the dollar. That combo tends to boost overseas earnings for big multinationals once converted back into pounds. “The weaker pound is obviously beneficial for the multinationals,” Fiona Cincotta, senior market analyst at City Index, said. Reuters

Investors in spirits have been hunting for signs of demand holding steady, particularly in the U.S. and China. On Thursday, Rémy Cointreau topped quarterly sales estimates and highlighted better trading in the U.S., but it also warned that China remains tough, partly due to the late Chinese New Year.

Diageo is entering a new leadership phase. The company’s appointment of Dave Lewis — the former Tesco CEO and longtime Unilever executive — caught RBC Capital Markets analyst James Edwardes Jones off guard in a good way. He called it a “pleasant surprise” and added, “We think this is a good move.” At the same time, Kai Lehmann, senior analyst at Flossbach von Storch, warned the sector faces “structural headwinds” and stressed that Diageo’s brands require “revitalisation.” Reuters

February’s benchmark is tough to meet. Back in November, Diageo downgraded its full-year outlook, predicting fiscal 2026 sales would be flat or dip slightly, with operating profit growth limited to the low- to mid-single digits.

Traders will focus on sterling early in the next session and throughout the week. After that, risk appetite will come into play. On a daily basis, shifts in consumer staples or new signals from spirits rivals might have a bigger impact than a minor brand sale.

The risk is clear: selling assets won’t boost demand. If U.S. consumers continue cutting back on premium spirits, or if China’s appetite for high-end liquor remains weak, investors could shift their attention from neat portfolio adjustments to the bigger question of whether volumes and pricing are holding steady.

Diageo will release its interim results for the half-year ending Dec. 31 on Feb. 25. The firm has set a webcast for 07:05 UK time, followed by a live Q&A session at 09:30.

Shan Ahmed Khan is a senior markets reporter at TS2.tech, specializing in stocks, technology and macroeconomic trends. A graduate of the Lahore University of Management Sciences (LUMS), he previously worked in investment research and market analysis. His coverage helps readers understand the key developments influencing global financial markets and emerging industries.

Stock Market Today

  • Eli Lilly's Market Value Surges $76 Billion After Jaypirca European Approval and Medicare GLP-1 Coverage
    June 27, 2026, 10:19 AM EDT. Eli Lilly (NYSE:LLY) saw its stock jump 7.13% to close at $1,208.12 on June 26, 2026, adding roughly $75.7 billion in market value. The spike followed the European Medicines Agency's positive opinion on Jaypirca, a blood-cancer drug, and the pending U.S. FDA decision. Jaypirca's Q1 sales were $165 million, modest compared to the $8.66 billion from diabetes drug Mounjaro and $4.16 billion from obesity drug Zepbound. The U.S. Centers for Medicare & Medicaid Services starts the GLP-1 Bridge program on July 1, providing weight control drugs like Foundayo and Zepbound for $50 per fill for eligible Medicare patients. Health-care stocks rallied in response, with sector ETFs gaining sharply amid broader market tech weakness.

Latest articles

Moderna (NASDAQ:MRNA) price targets draw attention as shares rally into short holiday week

Moderna (NASDAQ:MRNA) price targets draw attention as shares rally into short holiday week

27 June 2026
Moderna soared 12.6% Friday on heavy volume after unveiling new in vivo CAR-T pipeline plans, closing at $67.27—52% above the mean analyst target but still 14.5% below Piper Sandler’s new $77 target. The rally followed Science Day updates, even as analysts note the main new asset is preclinical and cash burn continues, with $7.5B cash at March-end and a projected $3B R&D spend for 2026.
Texas Instruments stock slips into the weekend after AI-led surge; what TXN watchers track next
Previous Story

Texas Instruments stock slips into the weekend after AI-led surge; what TXN watchers track next

Texas Instruments stock: what to know after TXN dips, with jobs data and chip demand in focus
Next Story

Texas Instruments stock: what to know after TXN dips, with jobs data and chip demand in focus

Go toTop